SOHO 2022: Focus on GVHD
The GVHD rate was around 5% in patients receiving Orca-T, a high-precision, regulatory T-cell-engineered donor product.
GVHD occurred more with a fludarabine-based flipped conditioning regimen than with a cyclophosphamide-based flipped regimen.
The presence and number of clonal plasma cells in an autograft are predictive of posttransplant outcomes in multiple myeloma.
Noncryopreserved and cryopreserved peripheral blood stem cells (PBSC) lead to similar patient outcomes after transplant.
Most patients did not have extensive chronic GVHD after a mismatched transplant with this pretransplant conditioning regimen.
Patients transplanted with omidubicel had better quality of life than patients transplanted with umbilical cord blood.
Patients with CMML who developed GVHD after transplant were less likely to relapse than patients who did not develop GVHD.
More than half of patients receiving haploidentical HSCT had GVHD, but age was the only predictive factor for survival.
New research suggests that the first complete remission is the best time for allogeneic HSCT in extramedullary AML.
Large pericardial effusions leading to acute pericardial tamponade after transplant were not associated with acute GVHD.
Use of a female donor for a male undergoing HSCT can raise the risk of GVHD but did not significantly reduce survival.
Scores on GVHD risk assessments can predict a patient’s risk of mortality and their likelihood of responding to treatment.
The cumulative incidence of GVHD was higher in patients who received a low CD3-positive T-cell dose during transplant.
HSCT with antithymocyte globulin and posttransplant cyclophosphamide did not lead to chronic GHVD in most patients.
Most patients who received allogeneic HSCT with omidubicel did not develop chronic graft-versus-host disease (GVHD).
There are several risk factors for chronic GVHD in patients who received allogeneic haploidentical HSCT.
DSA did not lead to graft failure or impact the GVHD incidence in patients who received haploidentical HSCT.
Acute graft-versus-host disease may increase the risk of transplant-related mortality by sevenfold in certain patients.
Pre-transplant clofarabine and total body irradiation led to a 22% GVHD relapse-free survival rate in patients with leukemia.
Extracorporeal photopheresis, a treatment for GVHD, may function by inducing formation of neutrophil extracellular traps.
670 Madison Ave.
Manalapan, NJ 07726